← 返回前沿论文

黑色素瘤抗 PD-1 治疗中,外周血中肿瘤抗原反应性 T 细胞的早期消失与更优的临床结局相关

英文原题:Early disappearance of tumor antigen-reactive T cells from peripheral blood correlates with superior clinical outcomes in melanoma under anti-PD-1 therapy.

查看英文原题

Early disappearance of tumor antigen-reactive T cells from peripheral blood correlates with superior clinical outcomes in melanoma under anti-PD-1 therapy.

PubMed 2021/12/01(内容时间) J Immunother Cancer Q1 · IF 11.7(JCR 2025)

研究概要

我们的发现表明,黑色素瘤反应性T细胞从外周向肿瘤的浸润依赖于PD-1阻断,并暗示这在有效治疗中起着开创性作用。

研究思路结论见上方概要

抗程序性细胞死亡蛋白1(PD-1)抗体目前已被常规用于转移性黑色素瘤以及越来越多其他癌症的治疗,但仍只有一部分患者产生应答。迫切需要更好地理解其作用方式以及用于预测临床结局的生物标志物。肿瘤排斥反应主要由T细胞介导。我们此前已表明,血液中存在NY-ESO-1反应性和/或Melan-A反应性T细胞与治疗背景异质的黑色素瘤患者总生存期(OS)延长相关。在此,我们研究了此类反应性T细胞是否也能为接受PD-1免疫检查点阻断(ICB)治疗的转移性黑色素瘤的临床结局提供信息。

在总共111例IV期黑色素瘤患者的两个独立队列中,评估了ICB治疗前及治疗期间NY-ESO-1和Melan-A重叠肽库对外周血T细胞的刺激。在某些病例中,还可评估TIL(肿瘤浸润淋巴细胞)对此类应答的情况。通过细胞内细胞因子染色检测干扰素γ(IFN-γ)、肿瘤坏死因子(TNF)和CD107a来表征这些应答。采用数字病理学分析来量化肿瘤中NY-ESO-1和Melan-A的表达。终点为OS和PFS。

循环中初始存在的 NY-ESO-1 或 Melan-A 反应性 T 细胞在 ICB 期间变得不再可检测,这与经过验证的、延长的 PFS(HR:0.1;p>0.0001)和 OS(HR:0.2;p=0.021)相关。对选定病例的黑色素瘤组织评估表明,肿瘤驻留的 NY-ESO-1 和 Melan-A 反应性 T 细胞与疾病控制之间存在相关性,支持这样一种观点:主要在接受 ICB 获益的患者中,发生了与治疗相关的细胞从外周向肿瘤的隔离。

展开英文摘要原文

BACKGROUND: Anti-programmed cell death protein 1 (PD-1) antibodies are now routinely administered for metastatic melanoma and for increasing numbers of other cancers, but still only a fraction of patients respond. Better understanding of the modes of action and predictive biomarkers for clinical outcome is urgently required. Cancer rejection is mostly T cell-mediated. We previously showed that the presence of NY-ESO-1-reactive and/or Melan-A-reactive T cells in the blood correlated with prolonged overall survival (OS) of patients with melanoma with a heterogeneous treatment background. Here, we investigated whether such reactive T cells can also be informative for clinical outcomes in metastatic melanoma under PD-1 immune-checkpoint blockade (ICB). METHODS: Peripheral blood T cell stimulation by NY-ESO-1 and Melan-A overlapping peptide libraries was assessed before and during ICB in two independent cohorts of a total of 111 patients with stage IV melanoma. In certain cases, tumor-infiltrating lymphocytes could also be assessed for such responses. These were characterized using intracellular cytokine staining for interferon gamma (IFN-γ), tumor negrosis factor (TNF) and CD107a. Digital pathology analysis was performed to quantify NY-ESO-1 and Melan-A expression by tumors. Endpoints were OS and progression-free survival (PFS). RESULTS: The initial presence in the circulation of NY-ESO-1- or Melan-A-reactive T cells which became no longer detectable during ICB correlated with validated, prolonged PFS (HR:0.1; p>0.0001) and OS (HR:0.2; p=0.021). An evaluation of melanoma tissue from selected cases suggested a correlation between tumor-resident NY-ESO-1- and Melan-A-reactive T cells and disease control, supporting the notion of a therapy-associated sequestration of cells from the periphery to the tumor predominantly in those patients benefitting from ICB. CONCLUSIONS: Our findings suggest a PD-1 blockade-dependent infiltration of melanoma-reactive T cells from the periphery into the tumor and imply that this seminally contributes to effective treatment.

论文信息

作者
Bochem J、Zelba H、Spreuer J、Amaral T、Wagner NB、Gaissler A、Pop OT、Thiel K
第一作者单位
Department of Dermatology, University Medical Center, Tübingen, Germany.Germany
通讯作者单位
Department of Dermatology, University Medical Center, Tübingen, Germany kilian.wistuba-hamprecht@uni-tuebingen.de.Germany
文献类型
非美国政府资助研究
期刊
Journal for immunotherapy of cancer2021 Dec
原文标识
PubMed 34933966 · DOI 10.1136/jitc-2021-003439